Mousavifar L - Search Results

1

Exploiting the DNA Damaging Activity of Liposomal Low Dose Cytarabine for Cancer Immunotherapy.

Lewicky JD, Martel AL, Fraleigh NL, Picard E, Mousavifar L, Nakamura A, Diaz-Mitoma F, Roy R, Le HT. Lewicky JD, et al. Among authors: mousavifar l. Pharmaceutics. 2022 Dec 3;14(12):2710. doi: 10.3390/pharmaceutics14122710. Pharmaceutics. 2022. PMID: 36559204 Free PMC article.

2

Development of Mannopyranoside Therapeutics against Adherent-Invasive Escherichia coli Infections.

Mousavifar L, Touaibia M, Roy R. Mousavifar L, et al. Acc Chem Res. 2018 Nov 20;51(11):2937-2948. doi: 10.1021/acs.accounts.8b00397. Epub 2018 Oct 5. Acc Chem Res. 2018. PMID: 30289687

3

Comparative Study of Aryl O-, C-, and S-Mannopyranosides as Potential Adhesion Inhibitors toward Uropathogenic E. coli FimH.

Mousavifar L, Vergoten G, Charron G, Roy R. Mousavifar L, et al. Molecules. 2019 Oct 2;24(19):3566. doi: 10.3390/molecules24193566. Molecules. 2019. PMID: 31581627 Free PMC article.

4

The Global Emergency of Novel Coronavirus (SARS-CoV-2): An Update of the Current Status and Forecasting.

Hozhabri H, Piceci Sparascio F, Sohrabi H, Mousavifar L, Roy R, Scribano D, De Luca A, Ambrosi C, Sarshar M. Hozhabri H, et al. Among authors: mousavifar l. Int J Environ Res Public Health. 2020 Aug 5;17(16):5648. doi: 10.3390/ijerph17165648. Int J Environ Res Public Health. 2020. PMID: 32764417 Free PMC article. Review.

5

Recent development in the design of small 'drug-like' and nanoscale glycomimetics against Escherichia coli infections.

Mousavifar L, Roy R. Mousavifar L, et al. Drug Discov Today. 2021 Sep;26(9):2124-2137. doi: 10.1016/j.drudis.2021.02.025. Epub 2021 Mar 3. Drug Discov Today. 2021. PMID: 33667654 Review.

6

Design, Synthetic Strategies, and Therapeutic Applications of Heterofunctional Glycodendrimers.

Mousavifar L, Roy R. Mousavifar L, et al. Molecules. 2021 Apr 22;26(9):2428. doi: 10.3390/molecules26092428. Molecules. 2021. PMID: 33921945 Free PMC article.

7

Novel immunomodulatory properties of low dose cytarabine entrapped in a mannosylated cationic liposome.

Martel AL, Fraleigh NL, Picard E, Lewicky JD, Pawelec G, Lee H, Ma GW, Mousavifar L, Roy R, Le HT. Martel AL, et al. Among authors: mousavifar l. Int J Pharm. 2021 Sep 5;606:120849. doi: 10.1016/j.ijpharm.2021.120849. Epub 2021 Jul 1. Int J Pharm. 2021. PMID: 34216770 Free article.

8

Recent Development in the Design of Neoglycoliposomes Bearing Arborescent Architectures.

Mousavifar L, Abdullayev S, Roy R. Mousavifar L, et al. Molecules. 2021 Jul 15;26(14):4281. doi: 10.3390/molecules26144281. Molecules. 2021. PMID: 34299556 Free PMC article. Review.

9

Improving the Utility of a Dynorphin Peptide Analogue Using Mannosylated Glycoliposomes.

Lewicky JD, Fraleigh NL, Martel AL, Nguyen TM, Schiller PW, Mousavifar L, Roy R, Le AD, Funk D, Le HT. Lewicky JD, et al. Among authors: mousavifar l. Int J Mol Sci. 2021 Jul 27;22(15):7996. doi: 10.3390/ijms22157996. Int J Mol Sci. 2021. PMID: 34360762 Free PMC article.

10

Synthesis & Evaluation of Novel Mannosylated Neoglycolipids for Liposomal Delivery System Applications.

Mousavifar L, Lewicky JD, Taponard A, Bagul R, Rivat M, Abdullayev S, Martel AL, Fraleigh NL, Nakamura A, Veyrier FJ, Le HT, Roy R. Mousavifar L, et al. Pharmaceutics. 2022 Oct 26;14(11):2300. doi: 10.3390/pharmaceutics14112300. Pharmaceutics. 2022. PMID: 36365120 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16 results

Search Page

Filters